MD Anderson, Exscientia collaborate to develop oncology treatments using AI

UVA scientists use AI to improve success rate for new drugs, reduce costs

University of Virginia School of Medicine scientists have developed an approach to drug development and discovery that could dramatically accelerate the creation of new medicines.

April 03, 2026

Vol.52 No.13

Clinical Roundup

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

Researchers from The University of Texas MD Anderson Cancer Center have found that simultaneously blocking two key “don’t eat me” signals found in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in models of glioblastoma, highlighting a promising strategy.

March 27, 2026

Vol.52 No.12

Clinical Roundup

GPSai AI algorithm may help identify and correct misdiagnoses of cancer

By including AI algorithms as part of routine comprehensive molecular profiling, clinicians can uncover clinically significant misdiagnoses in cases labeled as lung squamous cell carcinoma, influencing treatment decisions and patient outcomes, according to a multi-institutional study.

March 27, 2026

Vol.52 No.12

In Brief

Washington Research Foundation awards $7M to UW Institute for Protein Design to advance AI-enabled enzyme development

Washington Research Foundation has awarded a $7 million grant to the University of Washington Institute for Protein Design to accelerate the development of new catalytic enzymes and protein-based technologies with applications across medicine, technology, and sustainability.

March 20, 2026

Vol.52 No.11

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

Vasan Yegnasubramanian, MD, PhD, is the director of Precision inHealth Medicine at Johns Hopkins. He spoke with Johns Hopkins Kimmel Cancer Center communications staff about how AI is transforming cancer research and treatment. The transcript of the conversation follows.

March 06, 2026

Vol.52 No.09

By John’s Hopkins Kimmel Cancer Center Communications

MD Anderson, Exscientia collaborate to develop oncology treatments using AI

YOU MAY BE INTERESTED IN

UVA scientists use AI to improve success rate for new drugs, reduce costs

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

GPSai AI algorithm may help identify and correct misdiagnoses of cancer

Washington Research Foundation awards $7M to UW Institute for Protein Design to advance AI-enabled enzyme development

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

Renew today!

Subscriber content

Never miss an issue!

Login